Review: New strategies for early dietary intervention in Alzheimer's disease

IF 0.5 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Nutrition Clinique et Metabolisme Pub Date : 2025-01-24 DOI:10.1016/j.nupar.2024.11.002

Jinyan Huang

引用次数: 0

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder for which the cause is currently unknown, which has implications for drug development. In recent years, blood biomarkers have shown great potential in the early diagnosis of AD, and rapid advances in disease-modifying therapies have opened new possibilities for early treatment. In this article, we review the latest research on biomarkers related to Alzheimer's diagnosis and discuss the prospects of preclinical interventions, such as the use of natural extracts and probiotics in disease-modifying therapies (DMTs) via the gut-brain axis and other pathways, which provide new ideas for future therapeutic strategies and management of Alzheimer's disease.

查看原文本刊更多论文

综述：阿尔茨海默病早期饮食干预的新策略

阿尔茨海默病（AD）是一种神经退行性疾病，其病因目前尚不清楚，这对药物开发具有重要意义。近年来，血液生物标志物在阿尔茨海默病的早期诊断中显示出巨大的潜力，而疾病修饰疗法的快速进展为早期治疗开辟了新的可能性。本文综述了与阿尔茨海默病诊断相关的生物标志物的最新研究进展，并对临床前干预的前景进行了展望，如利用天然提取物和益生菌通过肠-脑轴等途径进行疾病修饰治疗（DMTs），为未来阿尔茨海默病的治疗策略和管理提供新的思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutrition Clinique et Metabolisme 医学-内分泌学与代谢

CiteScore

0.80

自引率

16.70%

发文量

216

审稿时长

78 days

期刊介绍： Nutrition Clinique et Métabolisme is the journal of the French-speaking Society of Enteral and Parenteral Nutrition. Associating clinicians, biologists, pharmacists, and fundamentalists, the articles presented in the journal concern man and animals, and deal with organs and cells. The goal is a better understanding of the effects of artificial nutrition and human metabolism. Original articles, general reviews, update articles, technical notes and communications are published, as well as editorials and case reports.